Is Arrowhead’s plozasiran becoming the RNAi drug to watch in extreme triglyceride disorders?
Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.
How Codexis, Inc.’s ECO Synthesis platform could reshape industrial RNA production workflows
Explore why Codexis, Inc.’s latest RNA manufacturing advances could influence scalability, stereochemical control, and future siRNA production economics.
Arrowhead just unlocked Australia for REDEMPLO, but the bigger RNAi test starts now
Arrowhead has regulatory momentum in rare lipid disease. The harder test is turning REDEMPLO approval into durable global uptake.
Arrowhead’s plozasiran clears CHMP: what a positive opinion for FCS means for siRNA’s regulatory arc in Europe
Plozasiran clears CHMP but the real test is reimbursement. Europe’s HTA bodies will now decide whether clinical FCS diagnosis is enough.
Can Arrowhead Pharmaceuticals expand plozasiran without the Ionis patent fight becoming a commercial overhang?
Arrowhead Pharmaceuticals is advancing plozasiran fast, but can it overcome the Ionis patent dispute? Read the deeper legal and commercial analysis.
How Alnylam Pharmaceuticals is using new ACC.26 data to deepen the case for vutrisiran and zilebesiran
See why Alnylam Pharmaceuticals’ new ACC.26 data on vutrisiran and zilebesiran could reshape cardiovascular strategy and market expectations.
Arrowhead Pharmaceuticals strengthens plozasiran’s severe hypertriglyceridemia case with durable ACC.26 data
Arrowhead Pharmaceuticals’ plozasiran posted durable triglyceride reductions at ACC.26. Read what the long-term data could change next.
Can Sarepta Therapeutics prove RNA interference works in FSHD1 and DM1 with early Phase 1/2 data
Read why Sarepta Therapeutics’ first siRNA data in FSHD1 and DM1 could matter for rare disease drug development and investor sentiment.